Remy Luthringer, Minerva CEO
The FDA spells out 4 reasons why it hates Minerva’s NDA ideas — but the biotech is going for it anyway
To put it mildly, regulators at the FDA have a few problems with Minerva’s $NERV failed schizophrenia drug roluperidone.
The biotech spelled it out in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
